Full Press Release Details
CVRx Reports Second Quarter 2024 Financial and
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc.
(NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing
innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for
the second quarter of 2024.
"We are pleased with our solid second quarter results, driven
by another record quarter in our U.S. Heart Failure business. We remain extremely optimistic about the Barostim technology and our market
opportunity. Our recent leadership appointments have significantly bolstered our executive team, positioning us well to address key market
development priorities," said Kevin Hykes, President and Chief Executive Officer of CVRx. "Our focus is on continuing to broaden
therapy awareness, strengthen our clinical evidence, and improve patient access. With our innovative technology, expanding market presence,
and the depth of expertise on our expanded leadership team, we're well-positioned to drive Barostim towards becoming standard of care,
making a meaningful difference in the lives of those suffering from heart failure and other cardiovascular diseases."
Second Quarter 2024 Financial and Operating Results
Revenue was $11.8 million for the three months ended June 30,
2024, an increase of $2.3 million, or 24%, over the three months ended June 30, 2023.
Revenue generated in the U.S. was $10.7 million for the three months
ended June 30, 2024, an increase of $2.4 million, or 29%, over the three months ended June 30, 2023. HF revenue units in the
U.S. totaled 339 and 265 for the three months ended June 30, 2024 and 2023, respectively. HF revenue in the U.S. totaled $10.5 million
and $8.3 million for the three months ended June 30, 2024 and 2023, respectively. The increases were primarily driven by continued
growth in the U.S. HF business as a result of the expansion into new sales territories, new accounts, and increased physician and patient
awareness of Barostim.
As of June 30, 2024, the Company had a total of 189 active implanting
centers, as compared to 190 as of March 31, 2024. Active implanting centers are customers that have completed at least one commercial
HF implant in the last 12 months. The number of sales territories in the U.S. increased by three to a total of 42 during the three months
ended June 30, 2024.
Revenue generated in Europe was $1.1 million for the three months ended
June 30, 2024, a decrease of $0.1 million, or 6%, over the three months ended June 30, 2023. Total revenue units in Europe increased
to 63 for the three months ended June 30, 2024 from 56 in the prior year period. The number of sales territories in Europe remained
consistent at six for the three months ended June 30, 2024.
Gross profit was $9.9 million for the three months ended June 30,
2024, an increase of $1.9 million, or 24%, over the three months ended June 30, 2023. Gross margin was 84% for each of the three
months ended June 30, 2024 and June 30, 2023.
R&D expenses decreased $0.5 million, or 16%, to $2.8 million for
the three months ended June 30, 2024 compared to the three months ended June 30, 2023. This change was driven by a $0.4 million
decrease in consulting expenses and a $0.1 million decrease in compensation expenses.
SG&A expenses increased $4.7 million, or 28%, to $21.1 million
for the three months ended June 30, 2024 compared to the three months ended June 30, 2023. This change was primarily driven
by a $2.6 million increase in compensation expenses, mainly as a result of increased headcount, a $1.0 million increase in non-cash stock-based
compensation expense, a $0.4 million increase in advertising expenses, a $0.2 million increase in travel expenses, and a $0.2 million
increase in consulting expenses.
Other income, net increased $0.3 million for the three months ended
June 30, 2024, compared to the three months ended June 30, 2023. This increase was primarily driven by greater interest income
on our interest-bearing accounts.
Net loss was $14.0 million, or $0.65 per share, for the three months
ended June 30, 2024, compared to a net loss of $11.6 million, or $0.56 per share, for the three months ended June 30, 2023.
Net loss per share was based on 21.6 million weighted average shares outstanding for three months ended June 30, 2024 and 20.7 million
weighted average shares outstanding for the three months ended June 30, 2023.
As of June 30, 2024, cash and cash equivalents were $70.4 million.
Net cash used in operating and investing activities was $10.2 million for the quarter ended June 30, 2024. This is compared to net
cash used in operating and investing activities of $11.8 million for the three months ended March 31, 2024.
Leadership Team Expansion
During the quarter, the Company strengthened its executive team to
drive market development priorities. Key appointments include Robert John as Chief Revenue Officer, bringing over 25 years of sales leadership
experience in the medical device industry; Dr. Philip Adamson as Chief Medical Officer; Bonnie Handke as SVP of Patient Access, Reimbursement,
and Healthcare Economics; Jennifer Englund as SVP of Global Clinical Research to enhance clinical evidence; and Tonya Austin as Chief
Human Resources Officer. These strategic hires position CVRx to effectively address awareness, clinical, and patient access barriers as
it drives Barostim towards becoming standard of care for heart failure.
For the full year of 2024, the Company now expects:
For the third quarter of 2024, the Company expects to report total
revenue between $12.7 million and $13.7 million.
Webcast and Conference Call Information
The Company will host a conference call to review its results at 4:30
p.m. Eastern Time today. A live webcast of the investor conference call will be available online at the investor relations page of
the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers,
or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
CVRx is a commercial-stage medical device company focused on developing,
manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim is the
first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is
an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed
to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough
Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure
and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking
statements, including statements regarding our future financial performance (including our financial guidance regarding full year and
third quarter 2024 results), our anticipated growth strategies, anticipated trends in our industry, our business prospects and our opportunities.
In some cases, you can identify forward-looking statements by terms such as "may," "will," "should,"
"expect," "plan," "anticipate," "could," "outlook," "guidance,"
"intend," "target," "project," "contemplate," "believe," "estimate,"
"predict," "potential" or "continue" or the negative of these terms or other similar expressions,
although not all forward-looking statements contain these words.
The forward-looking statements in this press release are only predictions
and are based largely on our current expectations and projections about future events and financial trends that we believe may affect
our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history
of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single
product, Barostim; our limited commercial sales experience marketing and selling Barostim; our ability to demonstrate to physicians and
patients the merits of our Barostim; any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim;
our competitors' success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise
more attractive than Barostim; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers,
and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide; product
liability claims; future lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately
unsuccessful; any failure to retain our key executives or recruit and hire new employees; impacts on adoption and regulatory approvals
resulting from additional long-term clinical data about our product; and other important factors that could cause actual results, performance
or achievements to differ materially from those that are found in "Part I, Item 1A. Risk Factors" in our Annual
Report on Form 10-K for the year ended December 31, 2023, as such factors may be updated from time to time in our other filings
with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Mark Klausner or Mike Vallie